Variation in Sp1 binding sites correlates with expression of survivin in breast cancer

Xu,Qing; Liu,Mei; Xu,Ningzhi; Zhu,Hongxia

doi:10.3892/mmr.2014.2371

Variation in Sp1 binding sites correlates with expression of survivin in breast cancer

Authors:
- Qing Xu
- Mei Liu
- Ningzhi Xu
- Hongxia Zhu
View Affiliations

Affiliations: Laboratory of Cell and Molecular Biology and State Key Laboratory of Molecular Oncology, Cancer Institute and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
Published online on: July 10, 2014 https://doi.org/10.3892/mmr.2014.2371
Pages: 1395-1399

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin is the smallest member of the inhibitor of apoptosis (IAP) family and is deregulated in breast cancer, where it is associated with a poor overall prognosis. It is well established that survivin overexpression predominately occurs at the transcriptional level. Numerous transcription factors bind to specific sequences in the promoter regions of genes and are involved in transcriptional regulation. Specificity protein (Sp) 1 binding sites have been found in the promoter region of the survivin gene. The present study aimed to investigate whether variations in Sp1 binding sites affect survivin expression. Nested polymerase chain reaction followed by DNA sequencing were performed to analyze the survivin gene promoter region in 42 breast cancer tissue samples. Furthermore, survivin expression was assessed using immunohistochemistry. High survivin protein expression was found in 66.7% (28/42) of breast cancer tissue samples. In addition, 15 variations in seven Sp1 binding sites were detected in 12 samples and Sp1 binding site variation was found to be associated with low survivin expression in the 42 samples. These findings suggested that variations in Sp1 binding sites may be associated with survivin expression.

View Figures

View References

1	Li F and Ling X: Survivin study: an update of ‘what is the next wave’? J Cell Physiol. 208:476–486. 2006.
2	Li F: Survivin study: what is the next wave? J Cell Physiol. 197:8–29. 2003. View Article : Google Scholar : PubMed/NCBI
3	Jha K, Shukla M and Pandey M: Survivin expression and targeting in breast cancer. Surg Oncol. 21:125–131. 2012. View Article : Google Scholar : PubMed/NCBI
4	Altieri DC: New wirings in the survivin networks. Oncogene. 27:6276–6284. 2008. View Article : Google Scholar : PubMed/NCBI
5	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI
6	Guha M and Altieri DC: Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 8:2708–2710. 2009. View Article : Google Scholar : PubMed/NCBI
7	Waligórska-Stachura J, Jankowska A, Waśko R, et al: Survivin - prognostic tumor biomarker in human neoplasms - review. Ginekol Pol. 83:537–540. 2012.PubMed/NCBI
8	Sarti M, Pinton S, Limoni C, et al: Differential expression of testin and survivin in breast cancer subtypes. Oncol Rep. 30:824–832. 2013.PubMed/NCBI
9	Dedić Plavetić N, Jakić-Razumović J, Kulić A and Vrbanec D: Prognostic value of proliferation markers expression in breast cancer. Med Oncol. 30:5232013.
10	Song J, Su H, Zhou YY and Guo LL: Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol. 34:2053–2062. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xu C, Yamamoto-Ibusuki M, Yamamoto Y, et al: High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. Breast Cancer. Sep 12–2012.(Epub ahead of print).
12	Li X, Dang X and Sun X: Expression of survivin and VEGF-C in breast cancer tissue and its relation to lymphatic metastasis. Eur J Gynaecol Oncol. 33:178–182. 2012.PubMed/NCBI
13	Adamkov M, Kajo K, Vybohova D, Krajcovic J, Stuller F and Rajcani J: Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma. Neoplasma. 59:30–37. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kapoor S: Beyond pancreatic carcinoma: The close relationship between survivin levels and prognosis in systemic malignancies. World J Clin Oncol. 3:80–81. 2012. View Article : Google Scholar
15	Johnson ME and Howerth EW: Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 41:599–607. 2004. View Article : Google Scholar : PubMed/NCBI
16	Gazouli M, Tzanakis N, Rallis G, et al: Survivin −31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 24:145–150. 2009.
17	Li XB, Li SN, Yang ZH, Cao L, Duan FL and Sun XW: Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol. 32:236–242. 2013. View Article : Google Scholar : PubMed/NCBI
18	Xu Y, Fang F, Ludewig G, Jones G and Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 23:419–429. 2004. View Article : Google Scholar
19	Boidot R, Vegran F, Jacob D, et al: The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes Cancer. 47:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
20	Li F and Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J. 344:305–311. 1999. View Article : Google Scholar
21	Xu R, Zhang P, Huang J, Ge S, Lu J and Qian G: Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun. 356:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
22	Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV and Sverdlov ED: Functional significance of a putative Sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc). 73:1183–1191. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhang G, Zhu H, Wang Y, et al: Krüppel-like factor 4 represses transcription of the survivin gene in esophageal cancer cell lines. Biol Chem. 390:463–469. 2009.
24	Li Y, Xie M, Yang J, et al: The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple Sp1 binding sites in the proximal promoter. Oncogene. 25:3296–3306. 2006. View Article : Google Scholar
25	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
26	Chin K, DeVries S, Fridlyand J, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
27	King CR, Kraus MH and Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 229:974–976. 1985. View Article : Google Scholar : PubMed/NCBI
28	Banerji S, Cibulskis K, Rangel-Escareno C, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486:405–409. 2012. View Article : Google Scholar : PubMed/NCBI
29	Sjöblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science. 314:268–274. 2006.
30	Wood LD, Parsons DW, Jones S, et al: The genomic landscapes of human breast and colorectal cancers. Science. 318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
31	Kan Z, Jaiswal BS, Stinson J, et al: Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
32	Usary J, Llaca V, Karaca G, et al: Mutation of GATA3 in human breast tumors. Oncogene. 23:7669–7678. 2004. View Article : Google Scholar : PubMed/NCBI
33	Ly M, Valent A, Diallo G, et al: Gene copy number variations in breast cancer of Sub-Saharan African women. Breast. 22:295–300. 2013. View Article : Google Scholar : PubMed/NCBI
34	Orsetti B, Courjal F, Cuny M, Rodriguez C and Theillet C: 17q21–q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene. 18:6262–6270. 1999.
35	Kalikin LM, Frank TS, Svoboda-Newman SM, Wetzel JC, Cooney KA and Petty EM: A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors. Oncogene. 14:1991–1994. 1997. View Article : Google Scholar : PubMed/NCBI
36	Cheng ZJ, Hu LH and Huang SJ: Correlation of −31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng. 27:258–263. 2008.(In Chinese).
37	Jang JS, Kim KM, Kang KH, et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 60:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
38	Wang YH, Chiou HY, Lin CT, et al: Association between survivin gene promoter −31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 73:670–674. 2009.
39	Yang X, Xiong G, Chen X, et al: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 135:1341–1349. 2009. View Article : Google Scholar : PubMed/NCBI
40	Borbély AA, Murvai M, Szarka K, et al: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol. 60:303–306. 2007.
41	Wierstra I: Sp1: emerging roles - beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun. 372:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
42	Grant SF, Reid DM, Blake G, Herd R, Fogelman I and Ralston SH: Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet. 14:203–205. 1996. View Article : Google Scholar : PubMed/NCBI
43	Liu W, Innocenti F, Wu MH, et al: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 65:46–53. 2005.PubMed/NCBI
44	Miao X, Yu C, Tan W, et al: A functional polymorphism in the matrix metalloproteinase-2 gene promoter (−1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res. 63:3987–3990. 2003.
45	Yu C, Pan K, Xing D, et al: Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 62:6430–6433. 2002.PubMed/NCBI
46	Cheng Q, Ling X, Haller A, et al: Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol. 3:179–197. 2012.PubMed/NCBI
47	Estève PO, Chin HG and Pradhan S: Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 282:2615–2625. 2007.PubMed/NCBI